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The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in
patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received
intravenous docetaxel 65mgm
 2 plus oxaliplatin 120mgm
 2 on day 1 based on a 3-week cycle. Forty-two patients were enrolled in
the current study, among whom 39 were assessable for efficacy and all assessable for toxicity. One complete response and 18 partial
responses were confirmed, giving an overall response rate of 45.2% (95% confidence interval (CI); 31.7–59.7%). At a median follow-
up of 7.7 months, the median time to progression and median overall survival was 5.7 (95% CI; 4.3–7.2) months and 9.9 (95% CI;
7.8–12.0) months, respectively. Grade 3/4 neutropenia occurred in 11 patients (26.1%) and febrile neutropenia was observed in four
patients (9.5%). The common non-haematologic toxicity was fatigue (grade 1/2, 61.9%) and nausea (grade 1/2, 47.7%). The
combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
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Although the prognosis for advanced gastric cancer is poor,
combination chemotherapy has improved the quality of life and
overall survival compared with the best supportive care in several
randomised studies (Murad et al, 1993; Glimelius et al, 1994;
Pyrhonen et al, 1995). Among the various active chemotherapeutic
agents, cisplatin-based combination chemotherapy has been most
commonly used with a high response rate of 37–56% (Kim et al,
1993; Boku et al, 1999; Roth et al, 2000; Vanhoefer et al, 2001).
Docetaxel, a semi-synthetic taxoid developed in the eighties, is
derived from the needles of the European yew tree, Taxus baccata
(Pazdur et al, 1993), and phase II studies have shown that
docetaxel, alone or in combination with cisplatin, is active against
advanced gastric cancer (Sulkes et al, 1994; Roth et al, 2000; Bang
et al, 2002). Furthermore, the additive effect of docetaxel in
combination with 5-flourouracil/cisplatin for the treatment of
advanced gastric cancer was also reported in a randomised phase
III study (Van Cutsem et al, 2006).
Oxaliplatin is a third-generation platinum derivative, the activity
of which is based on the formation of DNA adducts that inhibit
replication and transcription. However, the adducts of oxaliplatin
appear to be more effective than cisplatin adducts with regard to
the inhibition of DNA synthesis (Schmidt and Chaney, 1993;
Mamenta et al, 1994; Woynarowski et al, 2000). In clinical studies,
oxaliplatin has also shown antitumour activity when given as a
monotherapy or in combination with 5-fluorouracil in patients
with various solid tumours including gastric cancer (Louvet et al,
2002; Al-Batran et al, 2004; Cassidy et al, 2004; Suh et al, 2005;
Park et al, 2006). In comparison with cisplatin, oxaliplatin exhibits
a favourable toxicity profile with a substantially lower rate of
nephrotoxicity, ototoxicity, and myelosuppression (Extra et al,
1990; Misset et al, 2001; Louvet et al, 2002; Al-Batran et al, 2004;
Suh et al, 2005; Park et al, 2006).
Since these two active agents have different anticancer mechanism
and little overlap in terms of their key side effects except
neurotoxicity, docetaxel, and oxaliplatin would appear to be a
good combination regimen. As such, in recent clinical studies, the
combination of docetaxel and oxaliplatin demonstrated active
antitumour effect and manageable toxicity profile in patients with
Received 7 August 2007; revised 4 December 2007; accepted 12
December 2007; published online 22 January 2008
*Correspondence: Dr HS Song, Department of Hematooncology,
Dongsan Medical Center, Keimyung University School of Medicine, 194
Dongsan-dong, Jung-ku, Daegu 700-712, Korea;
E-mail: shs7436@dsmc.or.kr
British Journal of Cancer (2008) 98, 542–546
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
slung cancer or ovarian cancer (Kouroussis et al, 2003; Raez et al,
2006; Ferrandina et al, 2007). However, there is no published data
on the efficacy of a combination of docetaxel and oxaliplatin as a
first-line treatment for advanced gastric cancer.
Therefore, we conducted a phase II study to evaluate the
response rate, time to progression, duration of response, overall
survival, and safety of a combination regimen of docetaxel plus
oxaliplatin in patients with advanced gastric cancer. The schedule
and doses of docetaxel and oxaliplatin in the present study were
determined according to previous dose finding and phase II study
(Kouroussis et al, 2003; Raez et al, 2006).
PATIENTS AND METHODS
Eligibility
All the patients involved in the current study had histologically
confirmed metastatic or recurrent gastric adenocarcinoma with at
least one unidimensionally measurable lesion. (i.e., a diameter
X1cm, as assessed by spiral computed tomography). The patients
were 19–70 years of age with a performance status of 0–2 on the
Eastern Cooperative Oncology Group (ECOG) scale. Plus, adequate
haematological (absolute neutrophil count X1.5 10
9l
 1, platelet
count X100 10
9l
 1, haemoglobin X9gdl
 1), renal (serum
creatinine p1.5mgdl
 1 and creatinine clearance X50mlmin
 1),
and hepatic (total bilirubinp1.5mgdl
 1 and serum transaminase
levelp2 times the upper limit of the normal range) levels were
also required. Patients who had received adjuvant chemotherapy
completed 4 weeks before entry were eligible. Patients were
ineligible if they had previously received palliative chemotherapy
or radiation therapy, or had other severe medical illnesses, central
nervous system metastasis, severe peripheral neuropathy, another
active malignancy, or history of anaphylaxis to drugs. The
institutional review board of each author’s institution approved
the protocol, and written informed consent was obtained from all
patients before enrolment.
Study treatment
The docetaxel 65mgm
 2 was administered through a 1-h
intravenous infusion on day 1. The oxaliplatin (Oxalpla
s, Yuhan
Co, Seoul, Korea) 120mgm
 2 was also administered after the
docetaxel infusion over 2-h on day 1. All patients were
premedicated with a dexamethasone (8mg b.i.d. from 1 day
before to 1 day after docetaxel infusion) to prevent hypersensitivity
reactions of docetaxel. Antiemetic treatment was routinely given
before each cycle of chemotherapy. The prophylactic use of a
colony-stimulating factor (CSF) was not permitted in the first
cycle. Chemotherapy was given every 3 weeks and continued until
disease progression, patient refusal, or an unacceptable toxicity up
to 9 cycles.
Dose modification
The next course of treatment began only when the neutrophil
count was X1.5 10
9l
 1, the platelet count was X75 10
9l
 1,
and any other treatment-related toxicities were less than or equal
to grade 1; otherwise, treatment was withheld for up to 2 weeks. If
adverse events did not improve to grade 0 or 1 after 3 weeks, the
patients were excluded from the study. Treatment was continued at
the same dose if patients experienced grade 1 toxicities or other
toxicities considered by the investigator unlikely to become serious
or life threatening (e.g., alopecia). For all other treatment-related
adverse events with a grade 2 intensity or higher, the dose
modification scheme described below was implemented. No dose
reduction was required after the first appearance of a grade 2
toxicity, although treatment was interrupted until the toxicity was
resolved to grade 0–1. The doses of docetaxel and oxaliplatin were
reduced by 20% in patients who experienced a second occurrence
of a given grade 2 toxicity or any grade 3 toxicity. If patients
experienced a third occurrence of a given grade 2 toxicity, a second
occurrence of a given grade 3 toxicity, or any grade 4 toxicity, both
doses were reduced by 40%. The docetaxel and oxaliplatin were
both discontinued if, despite a dose reduction, a given toxicity
occurred for a fourth time at grade 2, a third time at grade 3, or a
second time at grade 4. If adverse events did not improve to grade
0 or 1 after 3 weeks, the patients were excluded from the study.
Study assessments
A screening assessment, including a medical history, physical
examination, ECG, chest X-ray, and tumour assessment was
conducted within 2 weeks before starting treatment. Further
assessments conducted within 7 days before starting treatment
included vital signs, an ECOG performance status, and laboratory
tests. Complete blood counts were performed weekly during the
first cycle and every cycle thereafter, and biochemical tests
performed before each cycle. Tumours were measured every two
cycles until the tumour progressed. The tumour responses were
classified according to the response evaluation criteria in solid
tumours guidelines (Therasse et al, 2000). Patients with a complete
response or partial response required a confirmatory disease
assessment at least 4 weeks later. Adverse events were graded
according to National Cancer Institute Common Toxicity Criteria
version 3.0. Peripheral sensitive neuropathy was graded according
to the oxaliplatin-specific scale reported by previous study
(Caussanel et al, 1990). Dose intensity was defined as the total
amount of drug given (mgm
 2) divided by the number of weeks.
Statistical analysis
The current trial used a two-stage optimal design, as proposed
by Simon, with a 90% power to accept the hypothesis and 5%
significance to reject the hypothesis (Simon, 1989). Plus, the
current trial was designed to detect a response rate of 45% as
compared to a minimal, clinically meaningful response rate of
20%. Allowing for a follow-up loss rate of 10%, the total sample
size was 42 patients with a measurable disease. All enrolled
patients were included in the intention-to-treat analysis of efficacy.
The duration of response, time to progression (TTP), and survival
analyses were all estimated using the Kaplan–Meier method. The
duration of response was defined as the interval from the onset of a
complete response or partial response until evidence of disease
progression was found. Meanwhile, the TTP was calculated from
the initiation of chemotherapy to the date of disease progression,
while overall survival was measured from the initiation of
chemotherapy to the date of the last follow-up or death. The
statistical data were obtained using an SPSS software package
(SPSS 11.0 Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
From February to November 2006, a total of 42 patients were
enrolled in the current study from six centers. The characteristics
of the patients are summarised in Table 1. The median age was 58
(range, 29–70) years, with 33 males and nine females. Most of the
patients (85.7 %) had a good performance status (ECOG 0 or 1).
Thirty (71.4 %) patients had a metastatic disease, while 12 patients
had a recurrent disease after surgical resection (total or subtotal
gastrectomy) of the primary tumour. Distant lymph nodes and the
liver were the most common sites of the metastases. No patients
had received prior palliative chemotherapy or radiotherapy.
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Thirty-nine (92.9%) of the 42 patients were assessable for
response, with the remaining three being lost to follow-up or
patient refusal. All efficacy data are reported using the intent-to-
treat patient population. One case of complete response and 18
cases of partial response were confirmed, giving an overall
response rate of 45.2% (95% confidential interval [CI]; 31.7–
59.7%). The response characteristics are shown in Table 2. The
median duration of response in the 19 responding patients was 6.2
(95% CI; 4.8–7.6) months, while the median TTP for all patients
was 5.7 (95% CI; 4.3–7.2) months at a median follow-up duration
of 7.7 (range, 0.2–14.1) months (Figure 1). Twenty-five patients
(59.5%) received a second-line therapy, such as irinotecan,
capecitabine, S-1, or cisplatin after disease progression. Nineteen
patients had died at the time of the present evaluation. The
estimated median overall survival was 9.9 (95% CI; 7.8–12.0)
months with an estimated 1-year survival rate of 40.4±10.5%
(Figure 1).
Toxicity
The haematologic and non-haematologic toxicities that occurred
during the current study are summarised in Table 3. A total of 186
cycles (median 4; range: 1–9 cycles) were administrated in 42
patients assessable for toxicity. The most severe haematologic
adverse event was neutropenia, which occurred with a grade 3/4
intensity in 11 patients (26.1%) and in 38 cycles (20.4%). Plus,
febrile neutropenia was observed in four patients (9.5%). However,
all cases were successfully treated with antibiotics and G-CSF.
Nausea and fatigue were the most common non-haematologic
toxicities. Grade 1/2 nausea and fatigue was observed in 47.7 and
61.9% of patients, respectively. Seventeen (40.4%) patients also
experienced a grade 1/2 peripheral neuropathy. Yet, no grade 4
non-haematologic toxicity was observed. Six patients (14.3%)
were hospitalised due to treatment toxicities (four due to febrile
neutropenia, one due to pneumonia, and one due to general
weakness), and one patient died of pneumonia during this study.
The dose was reduced in 12 cycles and treatment delayed in nine
cycles. The treatment doses were modified for the following
reasons: haematologic toxicity (66.6%), neuropathy (16.6%),
Table 2 Tumour response (intention-to-treat analysis)
Response Number (n¼42, %)
a
Confirmed response 19 (45.2)
a
Complete response 1 (2.3)
Partial response 18 (42.9)
Stable disease 12 (28.6)
Progressive disease 8 (19.1)
Not assessable 3 (7.1)
a95% Confidence interval¼31.7–59.7%.
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Figure 1 Kaplan–Meier curves for time to disease progression (A) and
overall survival (B) for intention-to-treat population (n¼42). The median
time to progression and median overall survival was 5.7 and 9.9 months,
respectively.
Table 1 Patient characteristics
Characteristic Number of patients, n¼42 (%)
Age (years)
Median (range) 58 (29–70)
Male/female 33 (78.6)/9 (21.4)
ECOG performance status
0 5 (11.9)
1 31 (73.8)
2 6 (14.3)
Disease status
Metastatic 30 (71.4)
Recurrent 12 (28.6)
Location of primary tumour
Upper 6 (14.3)
Middle and lower 36 (85.7)
Metastatic sites
Lymph node 18 (35.3)
Liver 16 (30.8)
Peritoneum 9 (17.3)
Ovary 2 (3.8)
Others (lung, adrenal gland, pancreas) 6 (14.3)
Number of metastases
1 28 (66.7)
2 6 (14.3)
X3 8 (19.1)
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sfatigue (8.3%), and vomiting (8.3%). The mean dose intensity for
the docetaxel and oxaliplatin over all treatment cycles was
19.6mgm
 2 per week and 37.5mgm
 2 per week, corresponding
to 90.4 and 93.7% of the planned dose intensities, respectively.
DISCUSSION
In the current study, the combination chemotherapy of docetaxel
and oxaliplatin, which can be administered on an outpatient basis,
produced active antitumour activity, and a safe toxicity profile in
patients with advanced gastric cancer. The overall response rate
(45.2%), median TTP (5.7 months), and median overall survival
(9.9 months) following treatment with the present regimen were
comparable with previous results reported for cisplatin-based
combinations (Boku et al, 1999; Roth et al, 2000; Vanhoefer et al,
2001), where a continuous infusion of a 5-flourouracil (5-FU) and
cisplatin regimen achieved a response rate of 51% and median TTP
of 5.45 months (Vanhoefer et al, 2001), while docetaxel plus
cisplatin regimens achieved a response rate and median TTP of
48% and 6.6 months, respectively (Roth et al, 2000). However, in a
recent meta-analysis of randomised phase II and phase III studies
best survival results were achieved with three-drug regimens
containing 5-FU, an anthracycline, and cisplatin in patients with
advanced gastric cancer (Wagner et al, 2006).
Oxaliplatin, which is commonly used in the treatment of
colorectal cancer, has also been shown to be active and safe in
the treatment of locally advanced or metastatic gastric cancer
(Louvet et al, 2002; Al-Batran et al, 2004; Suh et al, 2005; Park et al,
2006; Lee et al, 2007). A phase II study by Louvet et al (2002)
reported that an oxaliplatin, fluorouracil, and folinic acid
(FOLFOX6) regimen produced a high response rate of 44.9%,
and a recent phase II trial (Park et al, 2006) on oxaliplatin and
capecitabine combination chemotherapy also showed high re-
sponse rate of 65% and median progression-free survival of 7.5
months in patients with advanced gastric cancer. Furthermore,
oxaliplatin was found to be not inferior to cisplatin in a
randomised phase III study comparing capecitabine with fluouro-
uracil and oxaliplatin with cisplatin (Cunningham et al, 2006).
However, oxaliplatin-containing regimens might cause significant
peripheral neuropathy. Since there is no effective prophylaxis or
treatment for peripheral neuropathy, this can interrupt treatment
or reduce the dose intensity of oxaliplatin. For example, severe
(grade 3) peripheral neuropathy was observed in 21% of patients
and 9.4% of patients discontinued treatment due to neuropathy
in the FOLFOX6 regimen (oxaliplatin 100mgm
 2 every 2 weeks),
although it only occurred in patients benefiting from the
treatment, with a median cumulative dose of 901mgm
 2 (Louvet
et al, 2002). Accordingly, the current study used a reduced dose of
oxaliplatin (120mgm
 2 every 3 weeks) and chemotherapy was
given up to maximum 9 cycles, resulting in that no patient
experienced grade 3 neuropathy or discontinuation of treatment
and the dose intensity of oxaliplatin was 93.7%.
One of the major toxicities related to docetaxel is myelosuppres-
sion. Chemotherapy-induced severe neutropenia can also result in
treatment-related hospitalisation or mortality, thereby compro-
mising the quality of life and increasing medical expenditure. In
a previous study by Roth et al (2000) (docetaxel 85mgm
 2 and
cisplatin 75mgm
 2 based on 3-week intervals), grade 3/4
neutropenia was observed in 80% of patients and febrile
neutropenia in 16.7% of patients with advanced gastric cancer.
In a recent randomised trial reporting a higher response rate and
longer overall survival for a triplet of docetaxel, infusional
5-fluorouracil, and cisplatin compared to a doublet of infusional
5-fluorouracil and cisplatin, grade 3/4 neutropenia, and febrile
neutropenia also occurred in 84 and 16% of the patients receiving a
triplet regimen, respectively (Van Cutsem et al, 2006). However, in
the current study with a reduced dose of docetaxel (65mgm
 2
every 3 weeks), 11 patients (26.1%) experienced grade 3/4
neutropenia and four patients (9.5%) were hospitalised due to
febrile neutropenia. Furthermore, in a phase II study by
Ferrandina et al (2007) that employed docetaxel (75mgm
 2) and
oxaliplatin (100mgm
 2) for the second-line treatment of recurrent
ovarian cancer, 32.5% of patient experienced grade 3/4 neutropenia.
In conclusion, docetaxel plus oxaliplatin combination che-
motherapy was found to be well tolerated and effective in patients
with advanced gastric cancer. However, further studies are
warranted to clarify the role of this regimen compared to active
triplet regimens in the first-line treatment for advanced gastric
cancer.
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